Search
Talniflumate
go.drugbank.com/drugs/DB09295InvestigationalTalniflumate has been approved for approximately 20 years in Argentina other countries (excluding the United States, Europe, and Japan) [L1405].
Zanubrutinib
go.drugbank.com/drugs/DB15035ApprovedInvestigational[L39030] This indication is valid in the US, Europe, and Canada.
Cytisine
go.drugbank.com/drugs/DB09028InvestigationalAlso known as baptitoxine or sophorine, cytisine has been used as a smoking cessation treatment since 1964, and is relatively unknown in regions outside of central and Eastern Europe.
Reslizumab
go.drugbank.com/drugs/DB06602ApprovedInvestigationalReslizumab is marketed as Cinqaero in Europe.
Mifamurtide
go.drugbank.com/drugs/DB13615ApprovedInvestigationalMifamurtide is marketed in Europe as Mepact for intravenous infusion.
Hepatitis B Vaccine (Recombinant)
go.drugbank.com/drugs/DB11627ApprovedInvestigationalWithdrawnIn Canada, the United States and Northern Europe, 4% to 6% of the population are infected during their lifetime (mostly young adults); between 5% and 10% of infections lead to persistent viremia (carrier
Sirolimus
go.drugbank.com/drugs/DB00877ApprovedInvestigational[A242372] In November 2000, the drug was recognized by the European Agency as an alternative to calcineurin antagonists for maintenance therapy with corticosteroids.
Ranibizumab
go.drugbank.com/drugs/DB01270ApprovedInvestigational[A246399] Ranibizumab was initially approved by the FDA in 2006 [A2301] and by the European Commission (EC) in 2007.[L41429] It is marketed under the brand names LUCENTIS and SUSVIMO.
Remdesivir
go.drugbank.com/drugs/DB14761ApprovedInvestigational[L18438] Remdesivir was also approved by the European Commission on July 3, 2020.
Infliximab
go.drugbank.com/drugs/DB00065ApprovedInvestigationalInfliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions . Infliximab is produced by a recombinant cell line cultured by...